SCHEMBL21145693

SCHEMBL21145693

CCOc1cc(Cl)c(Cl)c(C=NNC(=O)c2ccc(C)cc2Cl)c1O

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LMNA P02545 2/20 0.52
CYP1A2 P05177 1/20 0.52
CYP3A4 P08684 1/20 0.52
MAPT P10636 1/20 0.52
CYP2C9 P11712 1/20 0.52
CYP2C19 P33261 1/20 0.52
HSD11B1 P28845 1/20 0.49
KMT2A Q03164 3/20 0.48
MEN1 O00255 2/20 0.48
ATM Q13315 2/20 0.48
PTK6 Q13882 1/20 0.48
PIK3CG P48736 4/20 0.47
TDP1 Q9NUW8 2/20 0.45
BACE1 P56817 1/20 0.44
NPC1 O15118 1/20 0.43
RAB9A P51151 1/20 0.43
KCNMA1 Q12791 1/20 0.42
CRHBP P24387 1/20 0.42
CRHR2 Q13324 1/20 0.42
ALPI P09923 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL21145691 1.00 LMNA (0.52) LMNACYP1A2CYP3A4MAPTCYP2C9
SCHEMBL21145735 0.87 PTK6 (0.48) LMNACYP1A2CYP3A4MAPTCYP2C9
SCHEMBL21145737 0.87 PTK6 (0.48) LMNACYP1A2CYP3A4MAPTCYP2C9
SCHEMBL21145696 0.86 IDO1 (0.53) LMNAMAPTKMT2AMEN1ATM
SCHEMBL21145698 0.86 IDO1 (0.53) LMNAMAPTKMT2AMEN1ATM
SCHEMBL21145676 0.84 KDM4E (0.52) LMNAMAPTKMT2AMEN1ATM
SCHEMBL21145677 0.84 KDM4E (0.52) LMNAMAPTKMT2AMEN1ATM
SCHEMBL21145704 0.83 POLB (0.47) LMNAMAPTKMT2AMEN1ATM
SCHEMBL21145727 0.82 ATM (0.62) LMNAMAPTKMT2AMEN1ATM
SCHEMBL21145724 0.82 ATM (0.62) LMNAMAPTKMT2AMEN1ATM

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11166924-B2 N-methyl-d-aspartate receptor allosteric modulators and methods for their use QINGDAO PRIMEDICINE PHARMACEUTICAL COMPANY, LTD. (CN) 2021-11-09 US disclosed
US-20190216753-A1 N-METHYL-D-ASPARTATE RECEPTOR ALLOSTERIC MODULATORS AND METHODS FOR THEIR USE QINGDAO PRIMEDICINE PHARMACEUTICAL COMPANY, LTD. (CN) 2019-07-18 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20190216753-A1 N-METHYL-D-ASPARTATE RECEPTOR ALLOSTERIC MODULATORS AND METHODS FOR THEIR USE GRIN2A, GRIN3A, GRIN1 LMNA 4679/4885CYP1A2 4595/4885CYP3A4 4513/4885
US-11166924-B2 N-methyl-d-aspartate receptor allosteric modulators and methods for their use GRIN2A, GRIN3A, GRIN1 LMNA 4679/4885CYP1A2 4595/4885CYP3A4 4513/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.